;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Headlines > Novo plans online launch for obesity pill once approved, Bloomberg News reports

Headlines

Novo plans online launch for obesity pill once approved, Bloomberg News reports

Published by Global Banking and Finance Review

Posted on October 3, 2025

Featured image for article about Headlines

(Reuters) -Danish drugmaker Novo Nordisk said it plans to make its new obesity pill available through telehealth platforms like Ro and WeightWatchers once it gets U.S. approval, Bloomberg News reported on Friday.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona)

More from Headlines

Explore more articles in the Headlines category

Trump says lawsuit against BBC likely to be filed soon

German parliament suffers suspected cyberattack during Zelenskiy’s visit, FT reports

European leaders agree Ukraine security guarantees should include European-led peacekeeping force

UK military chief urges Britain to better prepare for Russia threat

Ukraine says underwater drones hit submarine, but Moscow denies damage

Serbia's prosecutor files to indict minister in connection with Kushner project

French court jails Congo ex-rebel leader for 30 years

Italy's Caltagirone group strengthens governance procedure over Generali, MPS stakes

France says cattle disease under control as farm protests continue

Israeli forces kill Palestinian teen in West Bank, health ministry says

Ukraine could gain NATO-like security assurances in US-proposed Russia peace deal

European drone wall, other 'flagship' defence projects at risk in EU power struggle

View All Headlines Posts